227. オスラー病 Disease details / Clinical trials / Drug dev / DR info

Avastin
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2008   -   EUCTR2010-020545-26-IT   Italy
   HOSPICES CIVILS DE LYON
      2009   -   EUCTR2008-006755-44-FR   France
   Hospices Civils de Lyon
      2017   Phase 3   EUCTR2017-001031-39-FR   France
      2014   -   EUCTR2013-004204-19-FR   France
Avastin 25 MG/ML - konzentrat ZUR herstellung einer infusionsloesung
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria
Bevacizumab
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2008   -   EUCTR2010-020545-26-IT   Italy
   HOSPICES CIVILS DE LYON
      2009   -   EUCTR2008-006755-44-FR   France
   Hanny Al-Samkari, MD
      2020   Phase 2   NCT04404881   United States
   Hospices Civils de Lyon
      2017   Phase 3   NCT03227263   France
      2017   Phase 3   EUCTR2017-001031-39-FR   France
      2014   Phase 2/Phase 3   NCT02106520   France
      2014   -   EUCTR2013-004204-19-FR   France
      2011   Phase 1   NCT01507480   France
   James Gossage
      2011   Phase 2   NCT01408030   United States
   Medical University of Vienna
      2011   Phase 2   NCT01314274   Austria
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria
   Shandong Provincial ENT Hospital
      2021   Phase 4   ChiCTR2100043253   China
   Stanford University
      2014   Phase 4   NCT02389959   United States
   University of California, San Diego
      2009   Phase 2   NCT01397695   United States
Bevacuzimab spray
   University Hospital, Caen
      2014   Phase 1/Phase 2   NCT02157987   France
Blood samples
   Centre Hospitalier Universitaire Dijon
      2018   -   NCT03572556   France
Cord blood sampling
   Hospices Civils de Lyon
      2023   -   NCT05632484   France
Cord sampling
   Hospices Civils de Lyon
      2023   -   NCT05632484   France
Dicynone
   Asociación HHT España
      2017   Phase 2;Phase 4   EUCTR2016-003982-24-ES   Spain
Doxycycline hyclate
   Unity Health Toronto
      2018   Phase 2   NCT03397004   Canada
Emea/H/C/000712
   St. Antonius Hospital
      2019   Phase 2   EUCTR2019-003585-40-NL   Netherlands
Epistaxis charts
   Centre Hospitalier Universitaire Dijon
      2018   -   NCT03572556   France
Estriol
   James Gossage
      2011   Phase 2   NCT01408030   United States
Etamsylate
   Asociación HHT España
      2017   Phase 2;Phase 4   EUCTR2016-003982-24-ES   Spain
Ferrous sulphate 200MG oral tablet
   Imperial College London
      2013   -   NCT01908543   United Kingdom
Floseal
   St. Michael's Hospital, Toronto
      2015   -   NCT02638012   Canada
Itraconazole
   St. Antonius Ziekenhuis
      2018   Phase 2   EUCTR2017-003272-31-NL   Netherlands
Mupirocin
   Hospital Italiano de Buenos Aires
      2017   Phase 3   NCT02963129   Argentina
Nacl
   Medical University of Vienna
      2011   Phase 2   NCT01314274   Austria
Nintedanib
   Dr. Romain Lazor
      2022   Phase 2   NCT04976036   Switzerland
   Hospices Civils de Lyon
      2019   Phase 2   EUCTR2019-002593-31-FR   France
Nintedanib 150 MG and 100 MG soft capsules
   Hospices Civils de Lyon
      2020   Phase 2   NCT03954782   France
Nintédanib
   Hospices Civils de Lyon
      2019   Phase 2   EUCTR2019-002593-31-FR   France
Octreotide
   National Center for Research Resources (NCRR)
      1995   Phase 2   NCT00004327   -
   Radboudumc
      2021   Phase 3   EUCTR2018-004179-11-FR   France;Germany;Italy;Netherlands
      2019   Phase 3   EUCTR2018-004179-11-NL   Netherlands
Octreotide A azione pronta 0,1 MG
   RADBOUD UNIVERSITY MEDICAL CENTER
      2021   Phase 3   EUCTR2018-004179-11-IT   Denmark;France;Germany;Italy;Netherlands;United Kingdom
Octreotide acetate
   Radboudumc
      2020   Phase 3   EUCTR2018-004179-11-DE   France;Germany;Italy;Netherlands;United Kingdom
Octreotide acetato
   RADBOUD UNIVERSITY MEDICAL CENTER
      2021   Phase 3   EUCTR2018-004179-11-IT   Denmark;France;Germany;Italy;Netherlands;United Kingdom
Octreotide LAR
   Radboud University
      2016   Phase 2   NCT02874326   Netherlands
Ofev
   Hospices Civils de Lyon
      2019   Phase 2   EUCTR2019-002593-31-FR   France
Packing
   St. Michael's Hospital, Toronto
      2015   -   NCT02638012   Canada
Pazopanib
   Cure HHT
      2023   Phase 2/Phase 3   NCT03850964   United States
      2023   Phase 1/Phase 2   NCT03850730   -
Pegylated interferon alpha2B
   Mayo Clinic
      2007   Phase 2   NCT00588146   United States
Physiologische kochsalzloesung fresenius - infusionsloesung
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria
Pomalidomide
   The Cleveland Clinic
      2015   Phase 1   NCT02287558   United States
Pomalidomide oral product
   The Cleveland Clinic
      2019   Phase 2   NCT03910244   United States
Propranolol treatment
   University Hospital, Bordeaux
      2020   Phase 3   NCT04113187   France
Ranibizumab
   University of California, San Diego
      2011   Phase 1   NCT01406639   United States
RVG 18236
   Radboud University Medical Center
      2016   Phase 2   EUCTR2016-001340-19-NL   Netherlands
Sandostatin LAR 20 MG
   Radboud University Medical Center
      2016   Phase 2   EUCTR2016-001340-19-NL   Netherlands
Sclerotherapy
   University of Minnesota
      2011   Phase 1/Phase 2   NCT01408732   United States
Sirolimus
   Unity Health Toronto
      2022   Phase 2   NCT05269849   Canada
Sodium chloride
   Hospices Civils de Lyon
      2017   Phase 3   NCT03227263   France
   Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten
      2010   -   EUCTR2009-018049-19-AT   Austria
SOY protein isolate
   National Center for Research Resources (NCRR)
      1996   Phase 3   NCT00004654   -
Sporanox
   St. Antonius Ziekenhuis
      2018   Phase 2   EUCTR2017-003272-31-NL   Netherlands
Standard care
   Mayo Clinic
      2007   Phase 2   NCT00588146   United States
Standard treatment
   University of Minnesota
      2011   Phase 1/Phase 2   NCT01408732   United States
Sterile saline
   James Gossage
      2011   Phase 2   NCT01408030   United States
SUB16402MIG
   HOSPICES CIVILS DE LYON
      2009   -   EUCTR2008-006755-44-FR   France
Submucosal bevacizumab
   University of California, San Diego
      2010   Phase 2   NCT01402531   United States
Tacrolimus
   St. Antonius Hospital
      2019   Phase 2   EUCTR2019-003585-40-NL   Netherlands
   Unity Health Toronto
      2020   Phase 2   NCT04646356   Canada
Tamoxifen
   Rabin Medical Center
      2005   Phase 2   NCT00375622   Israel
Thalidomide
   IRCCS Policlinico S. Matteo
      2011   Phase 2   NCT01485224   Italy
   Northport Veterans Affairs Medical Center
      2006   Phase 2   NCT00389935   United States
Thalidomide celgene*28CPS 50MG
   OSPEDALE POLICLINICO S. MATTEO
      2011   Phase 2   EUCTR2011-004096-36-IT   Italy
Timolol alcon 0.5% collyre
   Hospices Civils de Lyon
      2015   Phase 2   EUCTR2015-000385-55-FR   France
Timolol GEL
   Washington University School of Medicine
      2019   Phase 2   NCT04139018   United States
Timolol maleate
   Hospices Civils de Lyon
      2015   Phase 2   EUCTR2015-000385-55-FR   France
Timolol nasal spray
   Hospices Civils de Lyon
      2015   Phase 2   NCT02484716   France
Topical timolol maleate
   Unity Health Toronto
      2013   -   NCT01752049   Canada
Tranexamic acid
   James Gossage
      2011   Phase 2   NCT01408030   United States
   University Hospital, Saarland
      2002   Phase 3   NCT01031992   Germany
VAD044 part I
   Vaderis Therapeutics AG
      2022   Phase 1/Phase 2   NCT05406362   Belgium;Canada;France;Italy;Netherlands;Spain;United States
VAD044 part II
   Vaderis Therapeutics AG
      2022   Phase 1/Phase 2   NCT05406362   Belgium;Canada;France;Italy;Netherlands;Spain;United States
VIT D
   St. Paul's Hospital, Canada
      2018   Phase 2   NCT03981562   Canada